Epidemiology of confirmed measles virus cases, surveillance, incidence, and associated factors in Eritrea: 18-year retrospective analysis
Author:
Mengistu Samuel Tekle1ORCID, Achila Oliver Okocht2ORCID, Tewelde Asmerom Tesfagiorgis3, Hamida Mohammed Elfatih4ORCID, Tekle Freweini5, Michae Issaias5, Said Mensura5, Fsahatsion Dawit5, Abai Haimanot5, Mulugeta Rahel5, TsigehanaTsegai 6, Woldu Luwam Gilazghi5, Werke Wintana Yebio7
Affiliation:
1. Nakfa Hospital, Ministry of health Northern Red Sea branch, Nakfa, Eritrea. 2. Orotta college of medicine and health sciences, unit of clinical laboratory sciences, Asmara, Eritrea. 3. IDSR, CDC, Ministry of Health, Asmara, Eritrea 4. Orotta college of medicine and health sciences, unit of microbiology, Asmara, Eritrea. 5. Serology department, National Health laboratory, Asmara, Eritrea 6. Serology department, National Health laboratory, Asmara, Eritrea Email: 7. Keren Hospital, Ministry of Health, Anseba branch, Keren, Eritrea
Abstract
Abstract
Background Understanding the incidence of laboratory-confirmed measles virus (MV) cases, related factors, and spatial inequalities in testing and surveillance is crucial to proving evidence-based decisions in measles prevention and control programs. In this analysis, our aim was to evaluate these factors in Eritrea.Methods Reviewed and analyzed a disease surveillance database from 2002 to 2020, used descriptive statistics and logistic regression, and calculated spatial variability and distribution of confirmed cases using ArcGIS Pro version 3.0.1 with a significance level of 5%.Results The median age (IQR) was 7 years (4–14 years) and the minimum-maximum age was 1 month – 97 years. In total, 9,111 suspected cases, 2,767 (1,431 (51.7%) females vs 1,336 (48.3%) males) were serologically tested. Among the 608 (21.9%) laboratory-confirmed cases, 534 (87.8%) were unvaccinated and 53 (9.92%) were < 1 year old. The crude incidence rate (CIR) for MV was 14/100,000 persons. The age-specific positivity rate per 100,000 suspected cases tested was 21.5 with individuals > 30 years presenting the highest rates, 69.9/100,000. The probability of test positivity was associated with an increasing age at the beginning of the rash (5–9 years: OR = 0.7, 95%CI: 0.5–0.9, p value = 0.02) (10–14 years: OR = 1.6, 95%CI: 1.1–2.2, p value = 0.005) (15–29 years: OR = 7, 95%CI: 5.3–9.2, p-value < 0.001) ( > = 30: OR = 16.7, 95%CI: 11.7–24, p-value < 0.001); Address (Anseba: OR = 2.3, 95%CI: 1.7–3.1, p-value < 0.001) (Debub: OR = 2.7, 95%CI: 1.9–3.9, p-value < 0.001) (Gash-Barka: OR = 15.4, 95%CI: 10.9–21.7, p-value < 0.001) (Northern Red Sea: OR = 11.8, 95%CI: 8.5–16.2, p-value < 0.001) (Southern Red Sea: OR = 14.4, 95% CI: 8.2–25.2, p-value < 0.001); Health facility (Health centre: OR = 2.5, 95%CI: 1.9–3.4, p-value < 0.001) (Hospital: OR = 6.8, 95%CI: 5.1–9.1, p-value < 0.001); Vaccination status (Unvaccinated: OR = 14.7, 95%CI: 11.4–19.1, p-value < 0.001); and year of onset of rash (2015: OR = 1.4, 95% CI: 1.1–1.7, p-value < 0.001). Interestingly, uptake of the measles vaccine (MCV) coverage was associated with a similar complement of factors.Conclusion The study concludes that efforts to eliminate measles in Eritrea are hindered by disparities in vaccine coverage and surveillance, and low vaccination rates in neighboring countries. The paper suggests that regional microplanning could be an effective strategy to improve surveillance and management in hard-to-reach regions.
Publisher
Research Square Platform LLC
Reference35 articles.
1. Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles Virus Host Invasion and Pathogenesis. Viruses. 2016 Jul 28;8(8). eng. Epub 2016/08/03. doi:10.3390/v8080210. Cited in: Pubmed; PMID 27483301. 2. de Vries RD, Duprex WP, de Swart RL. Morbillivirus infections: an introduction. Viruses. 2015 Feb 12;7(2):699–706. eng. Epub 2015/02/17. doi:10.3390/v7020699. Cited in: Pubmed; PMID 25685949. 3. Factsheet W. Measles. 2023 3 May. Available from: https://www.who.int/news-room/fact-sheets/detail/measles. 4. Trends of the global, regional, and national incidence of measles, vaccine coverage, and risk factors in 204 countries from 1990 to 2019;Wang R;Frontiers in Medicine,2022 5. What will it take to end human suffering from measles?;Thompson KM;The Lancet Infectious Diseases,2017
|
|